Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

Published

Journal Article

OBJECTIVE: This randomized, double-blind, placebo-controlled study evaluated the efficacy and tolerability of bupropion sustained-release (bupropion SR) in reducing weight and depressive symptoms in obese adults. RESEARCH METHODS AND PROCEDURES: Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet. Patients who lost <5% of baseline weight at week 12 had bupropion SR dosage or placebo increased to 400 mg/d in a blinded fashion. RESULTS: The bupropion SR group (n = 193) lost an average of 4.4 kg (4.6% of baseline weight) vs. 1.7 kg (1.8% of baseline weight) on placebo (n = 191, p < 0.001, last-observation-carried-forward analysis). More patients in the bupropion SR group than in the placebo group (40% vs. 16% of intent-to-treat sample, 50% vs. 28% of completers, respectively) lost at least 5% of baseline weight (p < 0.05 at week 4, p < 0.001 at weeks 6 to 26). The percentage of patients reporting > or =50% decrease in depressive symptoms did not differ between groups, but depressive symptoms improved more with bupropion SR than with placebo among patients with a history of major depression (p < 0.05, weeks 4 to 26). In the sample as a whole, improvement in depressive symptoms was related to weight loss of > or =5% regardless of treatment (p < 0.0001). Bupropion SR was well-tolerated. DISCUSSION: Bupropion SR in combination with a 500 kcal/d-deficit diet facilitated weight loss. Weight loss of > or =5% may improve mood in obese patients with depressive symptoms.

Full Text

Cited Authors

  • Jain, AK; Kaplan, RA; Gadde, KM; Wadden, TA; Allison, DB; Brewer, ER; Leadbetter, RA; Richard, N; Haight, B; Jamerson, BD; Buaron, KS; Metz, A

Published Date

  • October 2002

Published In

Volume / Issue

  • 10 / 10

Start / End Page

  • 1049 - 1056

PubMed ID

  • 12376586

Pubmed Central ID

  • 12376586

International Standard Serial Number (ISSN)

  • 1071-7323

Digital Object Identifier (DOI)

  • 10.1038/oby.2002.142

Language

  • eng

Conference Location

  • United States